Keyphrases
Infliximab
100%
Inflammatory Bowel Disease
99%
Crohn's Disease
84%
Treatment Failure
30%
Anti-infliximab Antibodies
30%
Ulcerative Colitis
30%
Remission
20%
Adalimumab
18%
Infliximab Therapy
15%
Tumor Necrosis Factor-α
15%
Pharmacokinetics
13%
Healthy Controls
11%
Drug Levels
11%
Randomized Controlled Trial
11%
Clinical Remission
11%
Confocal Laser Endomicroscopy
10%
Clinical Outcomes
10%
Ulcerative Colitis Patient
10%
Clinical Efficacy
9%
Anti-drug Antibodies
9%
Escherichia Coli
9%
Therapeutic Drug Monitoring
9%
Therapeutic Failure
9%
Dose Intensification
9%
Personalized Therapy
9%
LF82
8%
Maintenance Therapy
8%
Immunogenicity
8%
Severe Ulcerative Colitis
8%
Disease Activity
8%
Health-related Quality of Life
7%
Anti-TNF Therapy
7%
Infliximab Trough Level
7%
Loss of Response
7%
Intestinal Ultrasound
7%
Disease-specific
7%
Vedolizumab
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
Thiopurine Metabolites
7%
Radioimmunoassay
7%
Biologic Therapy
7%
Colectomy
6%
Infliximab Failure
6%
Anti-adalimumab Antibodies
5%
Thiopurines
5%
Disease Activity Score
5%
Anti-tumor Necrosis Factor Antibody
5%
Monotherapy
5%
Endoscopy
5%
Bowel Wall Thickness
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infliximab
80%
Inflammatory Bowel Disease
70%
Crohn's Disease
50%
Remission
22%
Ulcerative Colitis
19%
Tumor Necrosis Factor
18%
Adalimumab
14%
Pharmacokinetics
12%
Disease Activity
12%
Therapeutic Drug Monitoring
11%
Randomized Controlled Trial
11%
Vedolizumab
10%
Tumor Necrosis Factor Inhibitor
10%
Cohort Study
9%
Mercaptopurine
9%
Immunogenicity
7%
Bioavailability
7%
Disease
7%
Biological Product
6%
Trough Level
5%
Drug Antibody
5%
Tumor Necrosis Factor Antibody
5%
Monotherapy
5%
Medicine and Dentistry
Inflammatory Bowel Disease
35%
Ulcerative Colitis
27%
Infliximab
19%
Crohn's Disease
14%
Patient with Inflammatory Bowel Disease
13%
Confocal Laser Scanning Microscopy
10%
Disease
8%
Patient with Ulcerative Colitis
8%
Therapeutic Drug Monitoring
8%
Cohort Analysis
7%
Biological Therapy
7%
Systematic Review
7%
Adalimumab
7%
Vedolizumab
7%
Colectomy
6%
Disease Activity
6%
Endoscopy
5%
Biological Product
5%
Quality of Life
5%